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Abstract
This Pulmonary Perspective summarizes the content and main conclusions of an international workshop
on personalized respiratory medicine coorganized by the Barcelona Respiratory Network (www.brn.cat)
and the AJRCCM in June 2014. It discusses (1) its definition and historical, social, legal, and ethical
aspects; (2) the view from different disciplines, including basic science, epidemiology, bioinformatics,
and network/systems medicine; (3) the bottlenecks and opportunities identified by some currently
ongoing projects; and (4) the implications for the individual, the healthcare system and the
pharmaceutical industry. The authors hope that, although it is not a systematic review on the subject,
this document can be a useful reference for researchers, clinicians, healthcare managers, policy-makers,
and industry parties interested in personalized respiratory medicine.
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Because personalized medicine (PM) is a trending topic in biomedical science, it is pertinent to review
its scope and applicability to respiratory medicine. We summarize the content and main conclusions of
an international workshop on the topic coorganized by the Barcelona Respiratory Network
(www.brn.cat) and the AJRCCM in June 2014. As such, this manuscript is not a systematic review on
the topic but rather a potentially useful reference for researchers, clinicians, healthcare managers, policy
makers, and industry parties interested in personalized respiratory medicine.
Definition and Historical and Ethical Aspects
It can be argued that medicine has been personalized for the past 3,000 years, whenever an interaction
between a “healer/physician” and an ill person occurred (1). Why then the current interest in PM? The
answer likely relates to the development of new approaches to predict (and eventually to effectively
intervene) the individual risk of developing a disease, its severity, its evolution, and/or its response to
treatment, in contrast with traditional approaches that predict these risks for groups of patients (Figure 1
) (1, 2). Other terms used frequently in this field are defined in Box 1.
Figure 1.




The terms “P4 medicine” (Personalized, Predictive, Preventive, and Participatory) (83), “precision
medicine” (85), or “individualized medicine” (iMedicine) have often been used interchangeably
with personalized medicine (PM).
“Systems biology” is a research strategy that focuses more on the interactions between parts of a
biological system than on the components themselves. It seeks to understand and predict the
dynamics of a system, and it operates through iterative cycles of quantitative data collection,
computational modeling, and experimental validation in model systems (in silico, in vitro, or in
vivo) (86–88). “Systems medicine” (also called “network medicine” [7]) is a research strategy that
uses a similar approach in humans, both in health and disease (89).
“Stratified medicine” involves the use of statistical and bioinformatic analyses of different
biomarkers (molecular, clinical, functional, imaging, and others) to allow clinicians to classify
groups of patients (not individuals, like in PM) into more homogeneous groups with similar
prognosis and/or treatment needs in a real-life setting; as such, it is not a research strategy but rather
is an up-to-date clinical practice.
PM opens great opportunities but also raises significant ethical, legal, economic, and social issues, such
as (1) there are already companies commercializing predictive genetic information without fully
verified analytical and clinical validity (3), (2) it is unclear who will have access to and/or own this
Go to:
information in specific individuals (4), (3) relevant and current legislation is lacking in most countries
to avail and protect the individual (or patient) from the dissemination and potential misuse of predictive
information by third parties without the knowledge and approval of the individual, and (4) how
developing countries will be able to participate in and benefit from PM is unclear.
A Perspective of PM from Different Scientific Disciplines
The path to PM requires (1) interdisciplinary cooperation between basic, clinical, and epidemiological
research; (2) investment in infrastructure and resources, including bioinformatics data handling and
systems modeling approaches; and (3) decision support systems that allow the effective translation into
the clinic of all this new and complex knowledge (5).
The View from Basic Science: Addressing Biological Complexity!
The traditional reductionist approach of biomedical research has produced a vast amount of new
knowledge, best exemplified by the sequencing of the human genome in 2001 (6). However, it is now
also clear that biology is extremely complex (7). For instance, the recent mapping of the proteome in
2014 (8) and the “resilience projects” to map out why people stay healthy will provide further
understanding, and, as shown in Figure 2, the “determinants of a phenotype” include complex
epigenetic interactions between multiple spatial and time scales (Figure 3) mediated by nonlinear
biological networks that enable, filter, condition, and buffer such complex interplays (6, 9, 10).
“Nonlinearity” is the key concept here because it implies that the output of the “system” (e.g., having or
not having a disease) is not simply proportional to its “input” (e.g., risk factors) but is modulated in a
nonlinear way by different elements of these multilevel networks (Figure 2) (11).
Figure 2.
The “determinants of a phenotype” (the original concept of genes) include much more than DNA
sequences and depend on the complex gene–environment relationships filtered and modulated by many
biological networks. For further information, see text. Modified by permission from Reference 9.
Figure 3.
Different levels of complexity (from molecules to networks, cells, organs, and whole body) targeted by
different aspects of systems biology and network medicine. The spatial and dynamic scales that apply to
each level are also shown. Reprinted by permission from Reference 100.
A network can be represented as “nodes” and “edges” (11). Systems analysis shows that perturbations
of these networks may result in distinct functional consequences if they are due to node removal (i.e.,
complete loss of gene products) and/or edgetic (i.e., interaction [edge]-specific) alterations (12). The
complex, nonlinear, dynamic relationships between the parts of the system explain the occurrence of
emergent properties, such as health or disease (7, 13). For instance, a mutation can lead to a damaging
effect in one tissue and not in another, or two different mutations in the same protein could result in no
disease or cause different diseases due to quantitative effects on protein activity, competition for
binding, affinity, and relative concentration of binding partners (14). Likewise, exposure early in life to
an external or internal environmental stress may have a significant impact on the penetrance of a
mutation later in life. Finally, there is an element of randomness (stochastics) that changes dynamically
over time (in 20 yr, “you” will be a different “you”). As a result, in biology, the whole is over and above
its parts instead of just the sum of them all (14–16). The lack of consideration of these contextual effects
and the interactions between different elements and levels of the system likely explain the relatively
limited power of massive genome-wide association studies, which show little clinical effect of the
majority of associated genetic variants (17–19). The challenge is therefore to integrate multilevel,
multitype, dynamic (i.e., different measurements over time in the same individual [20]) information to
generate more powerful predictive models (Box 2).
Box 2.
The Challenge from Basic Science: Integration of Different Levels of Biological Complexity
The View from Epidemiology: A Key (but Sometimes Forgotten) Component of PM
Epidemiology can be defined as a population-based approach to health and disease. Starting with
epidemiological studies of smoking on respiratory health in the early 1950s (21), modern respiratory
epidemiology has largely evolved into a wide range of methods that allow us to understand causal
Take each type of data for itself (fingerprint) and combine them (using linear relationships or
more complex methods) to generate a handprint (90).
1.
Start with all raw data in the same scale, consider all potential relationships, and use unbiased
methods.
2.
relationships (at the population level) and to develop prediction models (for risk estimates in groups and
individuals). A relevant aspect of this evolution has been the use of biomarkers in molecular
epidemiology as a way to incorporate the biological mechanisms as part of the epidemiological causal
model. It is not a surprise, therefore, that some epidemiologists embraced genomics with hope. The
genome and postgenome respiratory epidemiology has evolved rapidly through genome-wide
association studies, the assessment of gene–environment interactions, and the other types of omics (22,
23). This has provided new insights and has stimulated research on causal mechanisms and on the use
of genetics for screening. However, the exponential increase of molecular and omics studies has
increased the amount and complexity of available information without resulting in better strategies for
the prevention and treatment of respiratory diseases (24–26) and has sometimes generated a feeling of
being lost in complexity. It is in this context that epidemiology can look to systems biology and PM as
an opportunity for more successful integrative strategies. Systems biology has developed a new
approach to complexity that includes networks as patterns of interrelationships and the possibility of
emergent properties, an approach that could contribute to a better understanding of complex respiratory
diseases like asthma. How respiratory epidemiology can contribute to personalized medicine is even
more challenging because the traditional risk factor epidemiology paradigm averages the risk of each
individual in the population (given their particular attributes) within the overall risk in the population
(27), whereas personalized medicine requires individual risk estimates, as discussed below. Box 3
presents potential different contributions of epidemiology to PM (28).
Box 3.
Contributions of Epidemiology to Personalized Medicine
Bioinformatics: The New Kid on the Block
There are increasingly large amounts of biological and clinically relevant information stored
electronically that can be useful to progress to PM (29). For instance, there are currently 23 million
scientific papers referenced in PubMed, and more than 700,000 are added each year, not to mention
additional medical knowledge beyond PubMed, including electronic medical records (30, 31). There is,
therefore, an opportunity to gain knowledge by overcoming the current fragmentation into “silos” (
Figure 4) (32). To achieve knowledge integration, a number of strategies and tools can be used that
leverage advances in computational, mathematical, and engineering sciences (Box 4) (32, 33). The
participation and close collaboration of basic and clinical scientists with bioinformaticians and
engineers is key for the proper curation and understanding of findings (33, 34). Several currently
available examples include, among others (35–37), the identification of novel candidate genes for
idiopathic pulmonary fibrosis (38, 39), personalized therapies for patients with cystic fibrosis (40), and
predictive outcome signatures in lung cancer (41).
Integration of different levels of biological, social, environmental, and behavioral complexity
(57)
1.
Unbiased study of population-based samples2.
Broadening statistical approaches to include bioinformatics analyses3.
Fostering, participating in, and leading multidisciplinary consortia4.




Knowledge engineering has the potential to overcome inter- and intradiscipline knowledge “silos.”
Reprinted by permission from Reference 32.
Box 4.
Bioinformatics Strategies and Tools Required to Advance toward Personalized Medicine
1. Seeking (i.e., mining), filtering, and prioritizing of information
2. Annotation and curation
3. Integrative analysis
4. Visualization in formats that are useful and user-friendly
Network/Systems Medicine
Major respiratory diseases, including chronic obstructive pulmonary disease (COPD) (2), asthma (42),
and idiopathic pulmonary fibrosis (43), are heterogeneous and complex. In this context, “complex”
means that these diseases result from the interplay of several components with nonlinear dynamic
interactions, whereas “heterogeneous” indicates that not all of these components are present in all
patients at any given time (2). Network medicine (Box 1) is a research strategy to study
comprehensively the molecular, cellular, disease, and social networks that underlie human diseases (44),
as discussed below (Box 5 shows the key components of network medicine [7]).
Box 5.
Key Components of Network Medicine
Holistic rather than reductionist approach1.
Construction of molecular, clinical, and social–environmental networks2.
Consideration of the nonlinear responses of complex systems3.
Assessment of emergent properties from the entire network(s)4.
Investigation of the dynamic responses of networks to various types of perturbations5.
Understanding disease pathobiologic complexity and disease subtypes
Development of new drugs
Clinical and unbiased
approaches, such as factor analysis or principal component analysis (which identifies disease axes) and
cluster analysis (which identifies groups of subjects), can be used to dissect disease heterogeneity (45).
Genetic studies may also help us to understand disease heterogeneity and to define disease subtypes
(e.g., six genomic regions so far have been associated with COPD [46]). Finally, the use of network
analysis allows the creation of molecular (11, 47) and phenotypic (34, 48, 49) networks that could
provide new insights into the pathobiology of the disease.
The reductionist approach to drug discovery has worked well in a number of
diseases (e.g., to develop antiretroviral agents for HIV infection) but has not been effective (yet?) in
many complex respiratory diseases. Because the latter likely results from multiple genetic, epigenetic,
molecular, cellular, tissular, organ, and environmental factors, targeting multiple components of disease
pathways may be necessary or even essential (50, 51) (Figure 5). For instance, the sequential use of
anticancer drugs enhances cell death by rewiring apoptotic signaling networks (52). Likewise, because
oncogenic signaling networks have multiple feedback levels, single protein measurements cannot
accurately predict cellular responses to drugs. This is also relevant for complex nonmalignant diseases,
such as many chronic respiratory diseases, in which tissue regeneration may be required. In fact, there
are respiratory drugs with pharmacogenomic labels, like indacaterol for COPD (53) and ivacaftor for
cystic fibrosis (40). Some of the challenges of developing subtype-specific therapy for chronic
respiratory diseases (COPD is used here as an example) are shown in Box 6.
Figure 5.
Current and network medicine approaches to drug development for complex diseases. Reprinted by
permission from Reference 50.
Box 6.
Challenges for Developing Subtype-Specific Therapy (Stratified Medicine) for Chronic Obstructive
Pulmonary Disease
1. Recognize that complex diseases result from biological network perturbations.
2. Identify subjects who have progressive versus stable disease to target individuals at risk for
progression with more intensive or different therapy; patterns of stability may vary between and
within biological subtypes.
3. Develop more sensitive and earlier readouts than FEV  decline or CT emphysema changes to
guide drug development.
Employment of systems biology methods6.
1
Reclassification of complex diseases
Go to:
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4. Acknowledge that some biological mechanisms could be rare, making specific treatment
development challenging.
When applied within the framework of network medicine, omics
technologies have the potential to provide insights into complex disease pathogenesis and to help create
reclassifications of disease that more precisely reflect pathogenesis and guide preventive, diagnostic
(e.g., imaging), and therapeutic strategies (54–56). Because long lead times are required to develop new
drug treatments, we anticipate that the initial clinical benefits of network medicine will be in improved
diagnoses based on disease reclassification, followed by renewed disease phenotyping, improved
prognostic information based on genomic and proteomic data, longitudinal studies of disease subtypes,
and eventually more effective treatments based on tailored therapeutic regimens.
Bottlenecks and Opportunities
There are several biology/systems and medicine/PM research projects currently ongoing in respiratory
medicine (57): (1) MEDALL (Mechanisms of the Development of Allergy), which aims to generate
novel knowledge on the mechanisms of initiation of allergy from early childhood to young adulthood
(58–60); (2) U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcome),
which hypothesized that biomarker profiles from high-dimensional molecular, physiological, and
clinical data integrated by an innovative systems medicine approach should enable the prediction of a
clinical course and therapeutic efficacy and identification of novel targets in severe asthma (17, 61); and
(3) Synergy-COPD (Modeling and Simulation Environment for Systems Medicine), whose working
hypothesis is that a systems approach to the understanding of chronic diseases (62) may enhance health
outcomes in a cost-effective manner (63, 64). Box 7 outlines potential bottlenecks and opportunities
facing these projects.
Box 7.
Bottlenecks and Opportunities of Systems Biomedicine Research Projects to Clinical Practice
(Network/Systems Medicine)
Implications for the Individual, Healthcare Systems, and the
Pharmaceutical Industry
As discussed below, personalized respiratory medicine has implications not only for the individual (who
is not necessarily a patient yet) but also for the healthcare system and the pharmaceutical and
biotechnology industry.
Individual Risk Stratification: Toward EBM 2.0
Evidence-based medicine (EBM) has affected the practice of medicine because it forced a reevaluation
of intuition, unsystematic empirical trial-and-error clinical experience, and pathophysiologic rationale
as sufficient grounds for clinical decision-making and, by contrast, has stressed the examination of
evidence from randomized clinical trials (RCTs) (65). Yet, by definition, RCTs deal with groups of
patients, not with single individuals, which is the essence of PM. EBM 2.0 aims at personalizing
Incorporate recent guidelines on omics analysis in clinical medicine (91, 92), limiting
preliminary discovery with proper external validation.
1.
Omics fingerprints have to be integrated with clinical data, requiring a quantitative, multiscale
systems approach.
2.
Large-scale pooling and harmonization3.
Assessing phenotypes using unbiased approaches4.
Developing appropriate knowledge management infrastructures (93)5.
Integrating pathobiological mechanisms into multilevel, multitissue, and multiscale models6.
Healthcare value
medicine through individual risk stratification and the consideration of personal values and preferences
(66).
The current practice of estimating benefits versus harms in an individual can be arbitrary (e.g., “it may
be worth a try”). The decision-making context is often oversimplified because only a single parameter
or few parameters are assessed (e.g., through comparing the number needed to treat and the number
needed to harm [67]), and personal informed participation is rare. The latter is particularly relevant in
the case of PM, when an individual (not yet a patient) may be offered a preventive treatment with a
potentially suboptimal efficacy/safety ratio to reduce the risk (high but not definite) of developing a
certain disease. How to deal with the issue of risk-seeking versus risk-averse individuals in this context
is unclear. However, to support clinical practice in this scenario, modern methods are emerging that
bring together personalized outcome risk assessment (from molecular and clinical characteristics),
preventive treatment effects (from RCTs), and personal preferences to estimate the benefit/harm balance
for individuals (68–71). In any case, it is essential to develop such individual risk-stratified treatment
strategies and well-defined translational paths that closely connect basic, clinical, and epidemiological
research with evidence synthesis and multidimensional benefit/harm analysis (Box 8) (28, 66). The goal
would be to develop clinical guidelines that support decision-making at the individual level rather than
for broader groups of patients, as is the case today. Besides individual risk prediction, it can also be
envisioned that individuals who nevertheless develop disease will be treated based on their genomic
profile (41).
Box 8.
Pathways for Individual Risk-stratified Assessment (66)
Implications for the Healthcare System(s)
Whether or not PM will increase healthcare value for the individual and for large
populations is of paramount importance (Box 9) (72). Yet, depending on the stakeholder, “value” may
be defined very differently. It has been suggested (73) that there are core elements of value (i.e.,
elements relating to patient health improvement) and wider elements of value (i.e., elements relating to
other benefits for the patient, and to benefits for caregivers, the health and social care systems, and
society more widely). The cost of this value is always a concern, although it is likely to vary in different
healthcare systems. Development of risk-sharing approaches between pharmaceutical companies and
healthcare-providing institutions has to be considered to provide equitable healthcare (74).
Box 9.
Healthcare Value (Outcomes/Cost) of Personalized Medicine
Outcomes
- Health gain per person
- Number of persons who might benefit from PM
- Access to the benefits of PM
Costs
- Healthcare system sustainability (71)
Precise identification of risk factors1.
Research on treatment effectiveness and risk prediction (94, 95) (i.e., combination of
biomarkers and clinical information in the prediction of outcomes [96, 97])
2.






PM may increase clinical practice variability, thereby increasing costs and
harms (1, 75). Generating the required scientific evidence for personalized treatments will be
challenging (28). One alternative is the analysis of big databases to identify subgroups of the population
who can benefit more (or less) from PM (31, 76).
PM involves not only the adoption of novel technologies; it also
proposes a radically different view of providing healthcare. For instance, disease classification is likely
to change (54, 57), and, as a result, healthcare organization will have to change (77, 78). Likewise,
different potential users of PM include patients (i.e., individuals with a disease), relatives of patients
(who may potentially have a higher risk of developing the disease), and/or healthy individuals interested
in knowing their risk and reducing it. The logistical and financial implications of considering these three
potential types of users will have to be addressed. As a result, (1) new or redesigned tools may be
needed (what will the future hospital/primary care practice look like?), (2) professional profiles and
roles (specialists, primary care providers, other healthcare providers, etc.) will have to be revisited, (3) it
is unclear whether healthcare services have enough resources to educate and pay PM-educated staff, and
(4) information and communication technologies and (wearable) sensors may play a key role. Finally, it
is known that life expectancy varies significantly with zip code, emphasizing the likely importance of
socio-economic and environmental factors, although zip codes could also track ethnic and therefore
genetic differences and would hence need to be handled while respecting privacy (79).
An Industry Perspective: Small Is Beautiful?
Introducing PM will be of interest and a challenge for the current business model of the pharmaceutical
industry. In fact, it has progressively moved from broad solutions for prevalent diseases to more focused
approaches in diseases with major unmet needs and lifelong suffering. Arguably, PM can mark the end
of the drug blockbuster era, in which one medication was used for one or more diseases, and the
beginning of more “tailored” approaches. However, this could initially drive costs up because it would
require the development of drugs for new targets (Figure 5) and would probably decrease the market
size for a specific medication. Pharmaceutical companies might be reluctant to invest in medications
with decreased markets and returns on investment. The question is therefore whether or not these small
indications (i.e., orphan diseases) can compensate for financial losses. Yet, the fact that many
age-related chronic diseases, the incidence of which is increasing in parallel with life expectancy (80),
share similar molecular mechanisms (34, 49) may reconcile “market size” with a “personalized
approach” through the identification of treatable clinical characteristics in these patients with
multimorbidities (2, 81).
Summary and Proposals for Future Development
Systems biomedicine has the potential to transform biomedical research and clinical practice from a
reactive to a proactive practice of medicine (20, 82). This transition requires a synergistic integration of
basic, clinical, and epidemiological approaches using computational modeling and knowledge
management sharing (83) (Box 10). As illustrated in Figure 6, PM can be then envisaged as the
convergence of three domains: excellence in clinical science and provision of care, omics and/or
imaging biomarkers, and network analysis coupled with clinical decision support systems. On the other
hand, the active participation of all stakeholders, including researchers, clinicians, other health
professionals, industry, regulatory and funding bodies, individual patients, patient organizations, and the
PM may result in increased costs and represent health gains to some but be denied to
others (“me” vs. “we” medicine) (98).
a.
Better prediction and prevention may reduce costs in the long term, but transitional
costs will be likely high.
b.
Comparative effectiveness can help to determine the effects of PM on the population
(99).
c.
Cost increases do not translate directly in better healthcare quality (100).d.
public in general, is necessary to address the associated ethical, legal, and social issues. Eventually, this
may result in a more cost-effective, efficient, and sustainable integrated healthcare system. There are
already examples of individuals who have managed to anticipate the occurrence of disease and take
preventive measures through a regular assessment of their own exposome (which includes their
environmental and occupational exposures, nutrition, sleep, exercise, and stress), clinicome (i.e., their
biological and clinical features), and integrome (integrated metabolomic, proteomic, transcriptomic,
epigenomic, genetic, and genomic features) (84). At this stage, however, it is essential to follow the
recent recommendations on the validation and implementation of complex biological information in
clinical medicine (3, 4).
Figure 6.




1.To progress to personalized medicine, research is needed and requires the following:
a. Consideration of key concepts, such as biological complexity (networks), multilevel data
integration, external data validation, population implications, and healthcare redesign





perturbations of the system in the same individual)
2. In the meantime, stratified medicine using appropriately validated biomarkers appears ready for
clinical use (81).
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